Search research articles
Contact Us
Filters
Showing results (201-210 of 317) with videos related to
Page
of 32
Sort By:
Immunity
|
November 22, 2011
T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex
Jarrett J Adams, Samanthi Narayanan, Baoyu Liu, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 15, 2018
Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy
Jamie B Spangler, Eleonora Trotta, Jakub Tomala, et al.
JCI Insight
|
September 5, 2023
Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2
Brendan L Horton, Alicia D D'Souza, Maria Zagorulya, et al.
Nature
|
March 12, 2026
Facile induction of immune tolerance by an interleukin-2-TGFβ surrogate agonist
Qinli Sun, Alison K Barrett, Masato Ogishi, et al.
Nature Communications
|
February 8, 2022
Mesenchymal-epithelial crosstalk shapes intestinal regionalisation via Wnt and Shh signalling
Martti Maimets, Marianne Terndrup Pedersen, Jordi Guiu, et al.
Nature
|
March 1, 2019
Structure of the IFNγ receptor complex guides design of biased agonists
Juan L Mendoza, Nichole K Escalante, Kevin M Jude, et al.
Elife
|
August 23, 2017
Deconstruction of the beaten Path-Sidestep interaction network provides insights into neuromuscular system development
Hanqing Li, Ash Watson, Agnieszka Olechwier, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
April 5, 2026
Corrigendum to "IL-34 exacerbates pathogenic features of Alzheimers disease and calvaria osteolysis in triple transgenic (3x-Tg) female mice" [Biomed. Pharmacother. 166 (2023) 115435]
Anny Ho, Bidii Ngala, Chiaki Yamada, et al.
Science (New York, N.Y.)
|
June 1, 2013
Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies
Kipp Weiskopf, Aaron M Ring, Chia Chi M Ho, et al.
Cell
|
August 23, 2011
Structural linkage between ligand discrimination and receptor activation by type I interferons
Christoph Thomas, Ignacio Moraga, Doron Levin, et al.
Page
of 32
Search research articles
Search
Showing results (201-210 of 317) with videos related to
Sort By:
Page
of 32
Immunity
|
November 22, 2011
T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex
Jarrett J Adams, Samanthi Narayanan, Baoyu Liu, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 15, 2018
Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy
Jamie B Spangler, Eleonora Trotta, Jakub Tomala, et al.
JCI Insight
|
September 5, 2023
Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2
Brendan L Horton, Alicia D D'Souza, Maria Zagorulya, et al.
Nature
|
March 12, 2026
Facile induction of immune tolerance by an interleukin-2-TGFβ surrogate agonist
Qinli Sun, Alison K Barrett, Masato Ogishi, et al.
Nature Communications
|
February 8, 2022
Mesenchymal-epithelial crosstalk shapes intestinal regionalisation via Wnt and Shh signalling
Martti Maimets, Marianne Terndrup Pedersen, Jordi Guiu, et al.
Nature
|
March 1, 2019
Structure of the IFNγ receptor complex guides design of biased agonists
Juan L Mendoza, Nichole K Escalante, Kevin M Jude, et al.
Elife
|
August 23, 2017
Deconstruction of the beaten Path-Sidestep interaction network provides insights into neuromuscular system development
Hanqing Li, Ash Watson, Agnieszka Olechwier, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
April 5, 2026
Corrigendum to "IL-34 exacerbates pathogenic features of Alzheimers disease and calvaria osteolysis in triple transgenic (3x-Tg) female mice" [Biomed. Pharmacother. 166 (2023) 115435]
Anny Ho, Bidii Ngala, Chiaki Yamada, et al.
Science (New York, N.Y.)
|
June 1, 2013
Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies
Kipp Weiskopf, Aaron M Ring, Chia Chi M Ho, et al.
Cell
|
August 23, 2011
Structural linkage between ligand discrimination and receptor activation by type I interferons
Christoph Thomas, Ignacio Moraga, Doron Levin, et al.
Page
of 32